Shenzhen New Industries Biomedical Engineering Co., Ltd. Stock price

Equities

300832

CNE100003T39

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-02-27 pm EST 5-day change 1st Jan Change
78 CNY -0.91% Intraday chart for Shenzhen New Industries Biomedical Engineering Co., Ltd. +0.44% -0.26%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 * 3.95B 549M Sales 2024 * 5.07B 705M Capitalization 61.29B 8.52B
Net income 2023 * 1.63B 227M Net income 2024 * 2.1B 292M EV / Sales 2023 * 15.3 x
Net cash position 2023 * 636M 88.31M Net cash position 2024 * 882M 123M EV / Sales 2024 * 11.9 x
P/E ratio 2023 *
37.5 x
P/E ratio 2024 *
29.2 x
Employees 2,818
Yield 2023 *
1.12%
Yield 2024 *
1.51%
Free-Float 39.41%
More Fundamentals * Assessed data
Dynamic Chart
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 86.13 Yuan From 75.19 Yuan, Keeps at Buy MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 75.19 Yuan From 71.58 Yuan, Keeps at Buy MT
Shenzhen New Industries' Profit Jumps 32% in H1 MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Nomura Adjusts Shenzhen New Industries Biomedical Engineering’s Price Target to 71.58 Yuan From 69.88 Yuan, Keeps at Buy MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 08 June 2023 CI
Shenzhen New Industries Biomedical Engineering's Shareholders Plan To Unload Company Stakes CI
Certain A Shares of Shenzhen New Industries Biomedical Engineering Co., Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2023. CI
Nomura Adjusts New Industries Biomedical's Price Target to 69.88 Yuan From 71.05 Yuan, Keeps at Buy MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shenzhen New Industries Biomedical Engineering Co., Ltd. Announces Profit Distribution Proposal for 2022 CI
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nomura Adjusts Shenzhen New Industries Biomedical Engineering’s Price Target to 71.05 Yuan From 67.87 Yuan, Keeps at Buy MT
Shenzhen Yinghe Brain Science Co., Ltd announced that it has received $14.800000 million in funding from Eli Lilly Investment Consulting Shanghai Co., Ltd., Shenzhen New Industries Biomedical Engineering Co., Ltd., Beijing Enlight Media Co., Ltd., Xi'an Xijiao 1896 Capital Management Co., Ltd., Shenzhen Qianhai BangQin Investment Co., Ltd. and other investors. CI
More news
1 day-0.91%
1 week+0.44%
Current month+12.90%
1 month+8.18%
3 months+12.55%
6 months+35.37%
Current year-0.26%
More quotes
1 week
73.35
Extreme 73.35
81.20
1 month
67.00
Extreme 67
81.20
Current year
67.00
Extreme 67
81.20
1 year
49.86
Extreme 49.86
81.20
3 years
31.76
Extreme 31.76
81.20
5 years
19.83
Extreme 19.8263
107.41
10 years
19.83
Extreme 19.8263
107.41
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 12-08-16
Director of Finance/CFO 49 04-09-30
Director/Board Member 31 16-05-31
Members of the board TitleAgeSince
Director/Board Member 49 12-07-31
Chief Executive Officer 60 12-08-16
Director/Board Member 61 18-09-09
More insiders
Date Price Change Volume
24-02-28 78 -0.91% 3,191,830
24-02-27 78.72 +1.20% 3,178,402
24-02-26 77.79 +4.98% 4,913,980
24-02-23 74.1 -0.83% 2,101,051
24-02-22 74.72 -0.47% 1,646,100

End-of-day quote Shenzhen S.E., February 27, 2024

More quotes
Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. The Company operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The Company sells its products both in domestic and international markets, including Asia, Europe, America and Africa.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
78 CNY
Average target price
76.31 CNY
Spread / Average Target
-2.17%
Consensus
  1. Stock
  2. Equities
  3. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd. - Shenzhen S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW